Literature DB >> 583162

Pharmacokinetics and relative bioavailability of oral theophylline capsules.

L J Lesko, A T Canada, G Eastwood, D Walker, D R Brousseau.   

Abstract

The oral bioavailability of liquid-filled theophylline capsules relative to a nonalcoholic aminophylline solution was determined in normal volunteers. In addition, theophylline absorption and elimination kinetics were reexamined. There were no statistically significant differences between the bioavailability of capsules and liquid as measured by the area under the curve (AUC) from time 0 leads to infinity (p greater than 0.05). The bioavailability parameters of Cmax, tmax, and AUC were determined from actual serum theophylline concentration-time data and from a nonlinear least-squares fit of the serum concentration-time data. Theophylline absorption from the capsules was noticeably faster than from the liquid in most subjects, although the differences in absorption rates were not significantly different (p greater than 0.05). The determined apparent volume of distribution, elimination half-life, and plasma clearance of theophylline were similar to values reported by other investigators. Marked inter- and intraindividual variations in the elimination half-life were noted.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 583162     DOI: 10.1002/jps.2600681114

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  3 in total

1.  Greatly enhanced bioavailability of theophylline on postprandial administration of a sustained release tablet.

Authors:  M Lagas; J H Jonkman
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Zero-order rectal delivery of theophylline in man with an osmotic system.

Authors:  L G de Leede; A G de Boer; S L van Velzen; D D Breimer
Journal:  J Pharmacokinet Biopharm       Date:  1982-10

3.  The effects of erythromycin on the absorption and disposition of kinetics of theophylline.

Authors:  T A Branigan; R A Robbins; W J Cady; J G Nickols; C T Ueda
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.